Why Repligen Corporation (RGEN) stock moved
Repligen Corporation (RGEN) shares climbed 10.9% to $145.34 as of July 28, 2026, a sharp gain from the prior close of $131.06. BestStocks flagged the session as a major change for RGEN. The move is tied to an earnings beat. Below, we break down what changed for RGEN, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
Earnings Beat
Repligen Corporation (RGEN) reported EPS of $0.54 vs. consensus estimate of $0.45, beating by 20.7% for Q2 FY2026 on July 28, 2026. RGEN has earnings scheduled for August 4, 2026 with a consensus EPS estimate of $0.46.
What it means for Repligen Corporation investors
For Repligen Corporation investors, the balance of recent signals points to a strong bullish shift. On the constructive side: Earnings beat with positive market reaction; Strong 10.9% price move with conviction. Weighing against that: Repligen Corporation (RGEN) moved -5.84% from $145.49 to $136.99 on 2026-07-21; New SEC filing — review for material disclosures. Wall Street's consensus price target sits at $152.00, implying +4.6% upside from $145.34. Over the past 90 days analysts logged 1 upgrade and 0 downgrades. BestStocks rates the overall signal quality high (82/100). With earnings roughly 91 days out, the next report is the most likely near-term test of the move.
RGEN price reaction
RGEN last traded at $145.34, up $14.28 (+10.90%) from the previous close of $131.06. The session traded on 2.0× average volume (very high), so the move carried above-average conviction. Over the past month the stock has ranged between $131.06 and $148.55, and it currently sits about 82% of the way up that band.
Bullish and bearish analyst opinions on Repligen Corporation (RGEN)
The consensus analyst price target on Repligen Corporation (RGEN) is $152.00, 4.6% above the recent $145.34. Over the past 90 days analysts logged 1 upgrade, 4 maintains, and 0 downgrades. Here is how the bullish and bearish cases on RGEN line up.
The bullish case
- Wall Street's consensus price target of $152.00 implies +4.6% upside from $145.34.
- The Street's most bullish target is $160.00 (+10.1%).
- 1 analyst upgrade in the past 90 days, most recently Benchmark to Buy (2026-07-07).
- Earnings beat with positive market reaction.
- Strong 10.9% price move with conviction.
The bearish case
- The most bearish analyst target is $142.00 (-2.3%).
- Repligen Corporation (RGEN) moved -5.84% from $145.49 to $136.99 on 2026-07-21.
Weighing both sides, BestStocks' composite read of recent signals is strongly bullish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Jul 28, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for RGEN
Frequently asked questions about RGEN
Why did Repligen Corporation (RGEN) stock move?
RGEN climbed 10.9% to $145.34. The move is associated with an earnings beat.
How much did RGEN stock rise?
RGEN gained 10.90% ($14.28) versus the prior close of $131.06, last trading at $145.34 on 2.0× average volume.
When is Repligen Corporation's next earnings date?
RGEN's next earnings report is estimated for 2026-10-27 — about 91 days away.
What is the analyst price target for RGEN?
The consensus analyst price target for RGEN is $152.00, about 4.6% above the current $145.34. Over the past 90 days, analysts recorded 1 upgrade, 4 maintains, and 0 downgrades.
How BestStocks tracks RGEN
This page is generated automatically by BestStocks' change-detection system after an earnings beat was detected and verified against independent data sources. It draws on 15 tracked change events for RGEN, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of July 28, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.